Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05221840 |
|---|---|
| Brief Title: | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) |
| First Submitted : | January 14, 2022 |
| First Submitted that Met QC Criteria : | February 2, 2022 |
| First Posted : | February 3, 2022 |
| Last Update Submitted that Met QC Criteria : | April 15, 2024 |
| Last Update Posted : | April 16, 2024 |